Please click here for a description of the business.
Please click here for the names of the directors and brief biographical details of each.
HUTCHMED is managed by a board of directors (the "Board") which consists of three executive directors, three non-executive directors and four independent non-executive directors (one of whom is senior independent director). The Board is responsible for directing the strategic objectives of HUTCHMED and overseeing the management of the business. Directors are charged with the task of promoting the success of HUTCHMED and making decisions in the best interest of HUTCHMED. The Board, led by the Chairman, approves and monitors the Group's long term objectives and commercial strategies, annual operating and capital expenditure budgets and business plans, evaluating the performance of HUTCHMED and supervising the management of HUTCHMED.
The Audit Committee
The Audit Committee reviews the Group's preliminary results, interim results and annual financial statements, oversees the relationship between HUTCHMED and its external auditors, monitors and reviews the effectiveness of HUTCHMED's internal audit function in the context of HUTCHMED's overall risk management systems giving due consideration to laws and regulations and the provisions of the UK Corporate Governance Code.
The Audit Committee is chaired by Mr. Graeme Jack and its other members are Mr. Paul Carter and Professor Tony Mok.
The Terms of Reference of the Audit Committee are available here.
The Remuneration Committee
The Remuneration Committee assists the Board in achieving its objective of attracting, retaining and motivating people of the highest caliber and experience needed to shape and execute strategy across the Group's substantial and diverse and international business operations. It ensures that the Group administers a fair and transparent procedure for setting remuneration policies including the assessment of the performance of Executive Directors and senior executives of the Group and determining their remuneration packages.
The Remuneration Committee is chaired by Mr. Paul Carter and its other members are Mr. Simon To and Mr. Graeme Jack.
The Terms of Reference of the Remuneration Committee are available here.
The Technical Committee
The Technical Committee considers from time to time matters relating to the technical aspects of research and development. It invites such executives as it deems appropriate to participate in meetings from time to time.
The Technical Committee is chaired by Professor Tony Mok and its other members are Mr. Paul Carter, Dr. Weiguo Su, Mr. Lefei Sun and Mr. Simon To.
The Terms of Reference of the Technical Committee are available here.
The Nomination Committee
The Nomination Committee reviews the structure, size, diversity profile and skills set of the Board against its needs and makes recommendations on the composition of the Board to achieve the Group corporate strategy as well as promotes shareholder value. It makes recommendations to the Board on the appointment or re-appointment of Directors, succession planning for Directors and selection of director candidates and senior management candidates. It also assesses the independence of Independent Non-executive Directors having regard to the criteria under the applicable corporate governance code or stock exchange rules and reviews Director Nomination Policy and Board Diversity Policy.
The Nomination Committee is chaired by Professor Tony Mok and its other members are Mr. Graeme Jack and Mr. Simon To.
The Terms of Reference of the Nomination Committee are available here.
The Sustainability Committee
The objectives of the Sustainability Committee is to oversee management and advise the board of directors (the “Board”) on the development and implementation of the corporate social responsibility and sustainability initiatives of the Group, including reviewing the related policies and practices, and assessing and making recommendations on matters concerning the Group’s sustainability development and risks.
The Sustainability Committee is chaired by Ms Edith Shih and its other members are Professor Tony Mok and Mr Johnny Cheng.
The Terms of Reference of the Sustainability Committee are available here.
HUTCHMED, incorporated in the Cayman Islands, is the holding company of a biopharmaceutical group with operations in China, the U.S. and Europe.
As HUTCHMED is a Cayman Islands incorporated company, the rights of shareholders may be different from the rights of shareholders in a UK incorporated company. Such rights are regulated by the Memorandum and Articles of Association of HUTCHMED and the Companies Law and common law of the Cayman Islands.
Please click for the Memorandum and Articles of Association.
The ordinary shares of HUTCHMED were admitted to trading on AIM regulated by the London Stock Exchange as well as on the Main Board of The Stock Exchange of Hong Kong Limited. HUTCHMED also has its securities admitted to trading on Nasdaq Stock Market in the form of American Depositary Shares.
Please click here for information on the number of ordinary shares of HUTCHMED and details of significant shareholders.
There are no restrictions on the transfer of securities in the Company.
Please click here for access to the Company's annual accounts for the last three years and interim reports since the last annual account.
Please click here to access notifications made by the Company in the past 12 months.
Please click here to access the Company's Admission Document dated 10 May 2006. However, please note that this document was issued well over ten years ago and is accordingly substantially out of date.
Please click here to access circulars sent to shareholders within the past 12 months.
Please click here to read the Statement of Compliance with the Hong Kong Corporate Governance Code.
HUTCHMED is subject to the Hong Kong Code on Takeovers and Mergers but is not subject to the UK City Code on Takeovers and Mergers or any other such legislation or code in its country of incorporation.
Please click here to access the Company's advisers.
Last updated: November 18, 2021